Tag: Parkinson’s

dbs long-term effectiveness

Long-term effectiveness of STN-DBS for Parkinson’s confirmed with 15-year follow-up study

New findings published in Neurology, the medical journal of the American Academy of Neurology (AAN), have confirmed the long-term effectiveness of deep brain stimulation...

Newronika announces CE mark for AlphaDBS system 

Newronika has announced the CE mark approval for its AlphaDBS system to treat Parkinson’s disease. According to a company press release, Newronika is a spin-off of the world-class neurological research centre Policlinico of Milan...

EVER Pharma launches patient friendly subcutaneous pump for Parkinson’s disease

EVER Pharma, a company specialising in neurological diseases, announces the launch of its D-mine  Pump. This portable micro infusion device recently received European CE...

New data show the therapeutic benefits of directional leads for use...

The PROGRESS study has achieved its primary endpoint and demonstrated superiority of the therapeutic window using Abbott directional stimulation compared to omnidirectional stimulation. Results...

DBS treatment may slow the progression of parkinson’s tremor in early-stage...

A study at Vanderbilt University Medical Centre, Nashville, USA has provided the first evidence of a treatment that slows the progression of one of...

Self-tuning brain implant could help treat patients with Parkinson’s disease

This study describes the first fully implanted DBS system that uses feedback from the brain itself to fine-tune its signalling. The study was supported...
vercise boston scientific

Positive late-breaking data from the INTREPID study announced

The one-year data from the INTREPID study, the first and only prospective, double-blind, randomised, sham-controlled, multi-centre study of deep brain stimulation (DBS) for advanced,...

FDA approves safinamide to treat Parkinson’s disease

The US Food and Drug Administration (FDA) has approved safinamide (Xadago) tablets as an add-on treatment for patients with Parkinson's disease who are currently...